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Summary
Background Maternal infections are an important cause of maternal mortality and severe maternal morbidity. We 
report the main findings of the WHO Global Maternal Sepsis Study, which aimed to assess the frequency of maternal 
infections in health facilities, according to maternal characteristics and outcomes, and coverage of core practices for 
early identification and management.
Methods We did a facility-based, prospective, 1-week inception cohort study in 713 health facilities providing obstetric, 
midwifery, or abortion care, or where women could be admitted because of complications of pregnancy, childbirth, 
post-partum, or post-abortion, in 52 low-income and middle-income countries (LMICs) and high-income countries 
(HICs). We obtained data from hospital records for all pregnant or recently pregnant women hospitalised with 
suspected or confirmed infection. We calculated ratios of infection and infection-related severe maternal outcomes 
(ie, death or near-miss) per 1000 livebirths and the proportion of intrahospital fatalities across country income groups, 
as well as the distribution of demographic, obstetric, clinical characteristics and outcomes, and coverage of a set of 
core practices for identification and management across infection severity groups.
Findings Between Nov 28, 2017, and Dec 4, 2017, of 2965 women assessed for eligibility, 2850 pregnant or recently 
pregnant women with suspected or confirmed infection were included. 70·4 (95% CI 67·7–73·1) hospitalised women 
per 1000 livebirths had a maternal infection, and 10·9 (9·8–12·0) women per 1000 livebirths presented with infection-
related (underlying or contributing cause) severe maternal outcomes. Highest ratios were observed in LMICs and the 
lowest in HICs. The proportion of intrahospital fatalities was 6·8% among women with severe maternal outcomes, 
with the highest proportion in low-income countries. Infection-related maternal deaths represented more than half of 
the intrahospital deaths. Around two-thirds (63·9%, n=1821) of the women had a complete set of vital signs recorded, 
or received antimicrobials the day of suspicion or diagnosis of the infection (70·2%, n=1875), without marked 
differences across severity groups.
Interpretation The frequency of maternal infections requiring management in health facilities is high. Our results 
suggest that contribution of direct (obstetric) and indirect (non-obstetric) infections to overall maternal deaths is 
greater than previously thought. Improvement of early identification is urgently needed, as well as prompt 
management of women with infections in health facilities by implementing effective evidence-based practices.
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Introduction
Maternal infections are an important cause of maternal 
mortality and severe maternal morbidity.1,2 Global 
estimates suggest that direct (obstetric) infections are 
the third most common cause of maternal mortality, 
representing about 10·7% of maternal deaths,1 with the 
largest toll estimated in low-income and middle-income 
countries (LMICs) at 10·7% compared with high-
income countries (HICs) at 4·7%.1 The contribution of 
infections to maternal deaths could be larger, as these 
figures do not include deaths due to abortion-related 
infections or indirect (non-obstetric) infections, which 
are not a result of, but aggravated by, pregnancy. 
Maternal deaths due to infection occur mainly through 
maternal sepsis, “a life-threatening condition defined as 
organ dysfunction resulting from infection during 
pregnancy, childbirth, post-abortion, or post-partum 
period”.3 This definition aligns with the recent Sepsis-3 
definition for adults4 and includes both direct and 
indirect infections.5,6
Accurate assessment of the burden of maternal 
infections and its complications, including sepsis, is 
Articles
e662 www.thelancet.com/lancetgh   Vol 8   May 2020
challenging given differences in case definitions and the 
populations studied. This assessment is further compli-
cated by the physiological changes during pregnancy that 
not only predispose women to and aggravate their 
response to infection, but also complicate its identification 
and management.7 Few studies have reported maternal 
infections across the continuum of pregnancy to post-
partum or post-abortion.8 The Global Burden of Disease 
study estimated that 11·9 million cases of direct maternal 
infections occurred in 2017.9 Generally, data for maternal 
sepsis in LMICs are scarce. The latest estimates on 
global burden of sepsis suggest that maternal disorders 
complicated with sepsis reached 5·7 million cases globally 
in 2017.10 Data from the 1990s suggested an incidence of 
1–2 cases per 1000 livebirths.11 Studies from the early-
2000s, mainly from HICs, reported lower incidences of 
0·1–0·6 per 1000 deliveries per year.7,8,12
The prevention, early diagnosis, and prompt manage-
ment of sepsis are key factors for reducing related 
morbidity and mortality, as reflected in the 2017 World 
Health Assembly resolution on sepsis.13 Several 
interventions, including trigger tools, appropriate use of 
antibiotics, and patient-care bundles improve monitoring 
and reduce infection-related deaths and severe morbidity, 
both in the general14 and the obstetric populations.15–17 
However, data as to how well these interventions are 
followed and how maternal infections are identified and 
managed in health facilities are scarce. This information 
is key for the implementation of quality improvement 
programmes and the reduction of preventable infection-
related maternal deaths and severe morbidities.
In 2017, WHO led the Global Maternal Sepsis Study 
(GLOSS) and Awareness Campaign in health facilities 
from 52 countries, under the umbrella of the “Global 
Maternal and Neonatal Sepsis Initiative”3 and in response 
to the World Health Assembly resolution on sepsis.13 The 
aim of the study was to improve understanding of the 
epidemiology and predictors of maternal infections and 
sepsis in health facilities, as well as current management 
and associated factors. We report here the main findings 
of GLOSS on frequency of maternal infections, according 
to demographic, obstetric, clinical characteristics, and 
outcomes, as well as coverage of core practices for early 
identification and management of maternal infections.
Methods
Study design and participants
We did a facility-based, prospective, 1-week inception 
cohort study in selected health facilities in 52 LMICs and 
HICs (figure 1). We identified all women with suspected 
or confirmed infection, during any stage of pregnancy 
and up to the 42nd day after end of pregnancy, admitted 
to or already hospitalised for at least 12 h in participating 
health facilities between Nov 28, and Dec 4, 2017, in 
purposively selected countries and geographical areas, 
based on prespecified criteria. 
Women who had a clinical suspicion or diagnosis of 
infection, a request for culture of any body fluid, or who 
Research in context
Evidence before this study
We identified primary studies and systematic reviews on 
frequency and management of maternal infections and sepsis 
using results of a previous systematic review by us, including 
searches in PubMed, MEDLINE, and Embase from Jan 1, 2010, 
to Feb 15, 2016, with no language restrictions (updated in 
September, 2019). We also identified WHO publications on 
the topic, and checked reference lists to identify additional 
studies. Globally, direct (obstetric) maternal infections are the 
third most common cause of maternal mortality, 
representing about 10·7% of all maternal deaths. Infections 
are also an important cause of indirect (non-obstetric) 
maternal deaths (eg, malaria, HIV, and influenza-like illness, 
among others). Globally, in 2017, there were approximately 
5·7 million women presenting with maternal disorders 
complicated with sepsis. The reported incidence of maternal 
sepsis varies across settings from 0·1 to 2·0 cases per 
1000 livebirths. However, the true burden of maternal sepsis 
and its complications is uncertain given the absence of 
standard definitions, identification criteria, and measurement 
tools, as well as variations in populations and sources of 
infections studied. It is globally recognised that prevention, 
early diagnosis, and prompt management of infections and 
sepsis are key factors for reducing related morbidity and 
mortality, as reflected in the 2017 World Health Assembly 
sepsis resolution.
Added value of this study
To the best of our knowledge, this is the first study to provide 
global data for the frequency and intrahospital management of 
maternal infections and its complications in 713 health facilities 
in 52 countries, across the continuum of pregnancy and post-
pregnancy timelines. This study provides insights on frequency 
of maternal infections, according to demographic, obstetric, 
clinical characteristics and outcomes, and coverage of core 
practices for the prevention, early identification, and 
management of maternal infections.
Implications of all the available evidence
Maternal direct and indirect infections are an important 
underlying and contributing cause of maternal mortality and 
severe morbidity. Improved understanding of epidemiological 
and clinical characteristics of maternal infections is key for 
sustaining the reduction of preventable maternal morbidity 
and mortality. To do so, further efforts are required for the 
development and implementation of comprehensive 
approaches for effective prevention, improved identification, 
monitoring, and management of maternal infections and 
sepsis in health facilities.
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were receiving antimicrobial treatment were eligible for 
inclusion (appendix p 1). All maternal deaths that 
occurred during the identification week, regardless of the 
cause, were also included. Women who presented with 
non-severe, localised, uncom plicated infection; uncompli-
cated chronic infection; bacterial colonisation; non-
infectious hypothermia or hyperthermia; or who received 
prophylactic antibiotics were not eligible as defined in the 
appendix (p 1). Women were followed up for up to 6 weeks 
or until hospital discharge, transfer to a health facility 
outside the study area, or death, whichever occurred first 
and regardless of pregnancy outcome. Nine women 
remained hospitalised at the end of the follow-up period, 
and their outcomes were collected at the time of discharge. 
Infants born to women included in the study were 
followed up for 7 days after birth or until hospital 
discharge, transfer outside the participating area, or 
death, whichever occurred first.
All health facilities providing obstetric, midwifery, or 
post-abortion care; or facilities with an emergency room, 
adult ward, intensive care unit or high dependency care; 
or any other setting where pregnant or recently pregnant 
women could be admitted because of pregnancy-related 
complications located within the selected geographical 
areas were eligible and invited to participate.
Ethical approvals were obtained from the WHO ethics 
review committee and as required by national or local 
entities. Women were informed about the study using 
posters placed in visible areas of the participating health 
facilities. In addition, study teams informed all eligible 
women about the study and the need to review their 
medical records for this purpose, as well as those of their 
neonates. Written informed consent or a waiver of 
written consent (opt-out) was obtained as required by 
local or national committees.
Details of the study protocol, including selection of 
countries, geographical areas, and facilities, have been 
published elsewhere.18 An awareness campaign targeting 
health providers accompanied the study.19
Procedures
Data were collected at the area, facility, and individual 
level using standardised paper forms specially designed 
for the study. These forms were based on tools used in 
previous multi-country surveys and existing facility 
assessment tools, and were customised and piloted for 
this study. Forms were translated from English into 
French, Portuguese, Russian, and Spanish, as well as 
additional official country languages by professional 
translators as needed. Data collection was standardised 
wherever possible and defined in the manual of 
operations designed for this study. A customised data 
entry and monitoring system was developed for the 
study.
Figure 1: Countries participating in the global maternal sepsis study
Eligible health facilities in purposively selected geographical areas in each country participated in the study. The boundaries shown on this map do not imply the 
expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, or concerning the delimitation of its frontiers or boundaries.
Countries included in analysis
Non-participating countries
See Online for appendix
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A single geographical area questionnaire was com-
pleted by country teams to collect information on the 
main characteristics of the area, including estimated 
population size and number of births (or deliveries) in 
2016. In each facility, a one-off facility questionnaire 
collected information on structural characteristics of 
each of the participating facilities: type of administration, 
location, level of specialisation, number of births in 2016 
and during the week of identification, and availability of 
maternity services and adult intensive care unit or high 
dependency care.
The individual data form collected information on 
demographic, obstetric, and clinical characteristics of the 
woman; characteristics of infections and management 
during stay in the health facility; and pregnancy, maternal, 
and neonatal outcomes. Infections could be confirmed 
using clinical examination alone, or comple mented by 
radiological, laboratory, or micro biological findings. 
Suspicion or confirmation of infection was undertaken as 
part of standard routine care in health facilities, and the 
study did not require additional collection of any 
laboratory, diagnostic, or other investigations. Abortion 
included any abortive outcome (induced abortion, 
miscarriage, ectopic, and molar pregnancy) as defined 
locally. Near-miss criteria (defined as a woman who nearly 
died but survived a life-threatening condition during 
pregnancy, childbirth, or post-partum or post-abortion 
periods) were not collected in six European countries 
(Belgium, Denmark, Italy, Spain, the Netherlands, the 
UK) as they implemented an adapted protocol using 
existing systems of surveillance of maternal morbidity. 
Inclusions were checked against hospital records, 
admissions to intensive care units or high dependency 
care, and for all maternal deaths during the identification 
week. Data quality assurance processes, including checks 
for accuracy and completeness of data, were put in place 
during data collection, data entry, and analysis.
Statistical analysis
A sample size of 2800 women was estimated to ensure at 
least 100 cases of severe maternal outcomes (ie, death or 
near-miss), based on a global birth rate of 19·6 livebirths 
per 1000 population per year, and assuming a 7% frequency 
of infections requiring hospital admission. Approximately 
50 geographical areas with 2 000 000 inhabitants would 
have to be included to cover about 40 000 births in 1 week.18
Women with infection were assigned to three groups 
according to the severity of the infection during hospital 
stay: (1) infection-related severe maternal outcomes 
included women presenting with WHO near-miss 
criteria to define organ system dysfunction2 or maternal 
death,5 and corresponds to the prespecified primary 
outcome of the study; (2) infections with complications 
included women with an invasive procedure to treat the 
source of infection (vacuum aspiration, dilatation and 
curettage, wound debridement, drainage [incision, 
percutaneous, culdotomy], laparotomy and lavage, other 
surgery), admission to intensive care unit or high 
dependency care, or transfer to another facility. This 
group constitutes a composite of prespecified secondary 
outcomes; (3) and the remaining were classified as less 
severe infections. We considered women with infection-
related severe maternal outcomes as a proxy for maternal 
sepsis,3 which includes infection associated with life-
threatening organ dysfunction or failure.
We estimated overall ratios of maternal infection 
(suspected or confirmed infections) and ratios of 
infection-related severe maternal outcomes (ie, death or 
near-miss) per 1000 livebirths in health facilities in 2016, 
and proportion of intrahospital fatalities among women 
with severe maternal outcomes, by country income, 
using the 2018 World Bank classifi cation. We calculated 
the distribution of maternal demographic, obstetric and 
clinical characteristics, complications, and outcomes by 
severity group. We calculated coverage of a core set of 
practices for early identification and management of 
maternal infections, including recording of a complete 
set of vital signs on day of suspicion or diagnosis of 
Figure 2: Study profile
Percentages are shown as n of total sample. There were 713 health facilities in 52 countries. *2580  women 
included using full protocol, 290 women included using modified protocol in western European countries 
(Belgium, Denmark, Italy, Spain, the Netherlands, the UK). †Source of infection clinically, radiologically, or 
microbiologically confirmed. ‡Includes women who had an invasive procedure to treat the source of infection 
(vacuum aspiration, dilatation and curettage, wound debridement, drainage [incision, percutaneous, culdotomy], 
laparotomy and lavage, other surgery), admission to intensive care or high dependency unit, or transfer to another 
facility. §Maternal death or near-miss. ¶At least one WHO near-miss criteria. ||Includes seven deaths due to direct 
(obstetric) cause, five due to abortion, six due to indirect (non-obstetric) cause (respiratory infection, meningitis, 
gastrointestinal). **Includes two deaths due to obstetric haemorrhage, one hypertensive disorder, one other direct 
cause, two indirect cause, two with unknown cause.
2850* women with suspected or 
confirmed† infections 
20 maternal deaths not related to infections 
during the week of identification 
 
1835 (64·4%) less 
severe maternal 
infections 
381 (13·4%) infection-
related severe 
maternal outcome§
 
634 (22·2%) maternal
infections with 
complications‡ 
26 (0·9%) infection-
related intrahospital
maternal deaths 
355 (12·5%) infection-
related maternal
near-miss¶
8 infection as 
contributing cause**
18 infection as 
underlying cause|| 
41 140 births covered during the 
week of identification  
2870 women included
For UN data see http://data.
un.org
For the World Bank 
classification see https://
datatopics.worldbank.org/world-
development-indicators/the-
world-by-income-and-region.
html
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infection, early initiation of therapeutic antibiotics or 
other anti microbials (initiated the same day of suspicion 
or diagnosis, or day after if suspicion or diagnosis was 
after 1800 h), drawing of any samples for culture before 
initiation of antibiotic therapy, and identification and 
control of the source of infection.
Maternal deaths without infections that occurred during 
the identification week were excluded from this analysis 
(n=20). Missing values were less than 10% for all 
sociodemographic variables, except schooling (54% of 
values missing), and less than 5% for all obstetric and 
other clinical characteristics and outcomes, except anaemia 
during pregnancy (33% missing), and neonatal status at 
end of follow-up (12%). Therefore, no additional analyses 
were undertaken to account for missing data. Two separate 
manuscripts are being developed to report on additional 
predefined primary and secondary outcomes, including 
identification criteria of severe maternal infection and 
sepsis, and the full set of neonatal outcomes.
Categorical variables are presented as proportions and 
continuous variables as medians and IQRs. 95% CIs for 
ratios were calculated using normal approximation. 
Comparisons between infection severity groups were 
obtained using ordinal multinomial mixed models for 
percentages and linear models for medians, adjusting for 
clustering at the country level. Statistical analyses were 
done using SAS version 9.4.
Role of the funding source
The funders of the study had no role in data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Of 2965 women assessed for eligibility, 2850 women 
were included in this analysis who were admitted for or 
already hospitalised with a suspected or confirmed 
infection (figure 2) in 713 facilities in 52 countries 
(408 facilities in 43 LMICs and 305 facilities in 
nine HICs). Participating facilities were mainly public, 
in urban locations, and tertiary or secondary level 
(appendix p 2). One participating low-income country 
was excluded from the study because we were unable to 
complete the prespecified data quality assurance process 
(six health facilities, 76 women). Six facilities in LMICs 
and 16 in HICs in the predefined geographical areas 
refused to participate. 19 eligible women refused to 
participate.
The ratio of intrahospital maternal infections 
(suspected or confirmed) was 70·4 (95% CI 67·7–73·1) 
women per 1000 livebirths (table 1) and 10·9 (9·8–12·0) 
of 1000 livebirths presented with infection-related 
severe maternal outcomes. The highest ratio was 
observed in upper-middle-income countries (106·4, 
95% CI 98·1–114·7) and the lowest in HICs (38·6, 
34·1–43·1; table 1). Differences across LMICs were less 
marked for infection-related severe maternal outcomes.
Intrahospital case fatalities among women with infection-
related severe maternal outcomes was 7% (26 of 381 women 
with severe maternal outcomes; figure 2). Higher case 
fatalities were found in low-income (12 [15%] of 81) and 
lower-middle-income (13 [7%] of 179) than in upper-middle-
income (one [1%] of 91) countries. No maternal deaths were 
reported in HICs. Infection was the underlying cause—
including direct and indirect infections—or contri buting 
cause in more than half of the intrahospital deaths that 
occurred in participating facilities during the identification 
week (19 of 39 maternal deaths; appendix p 3). Additional 
details of the distribution of organ dysfunction by system, 
causes of maternal deaths, and contribution of infections to 
maternal deaths are described in the appendix (pp 3–4).
Table 2 shows demographic, obstetric, and clinical 
characteristics of all women, and by infection severity 
groups. At eligibility, more than half of the women were 
Overall Low-income Lower-middle-income Upper-middle-income High-income
Countries 52 10 22 11 9
Livebirths in geographical areas in 2016 2 974 356 705 003 1 306 181 481 717 481 455
Women who had a maternal infection* 2850 484 1239 743 384
Women who had a maternal infection with complications† 634 123 307 147 57
Women who had an infection-related severe maternal 
outcomes‡
381 93 192 92 4
Ratio of maternal infection per 1000 livebirths 70·4 (67·7–73·1) 70·6 (64·1–77·0) 71·6 (67·5–75·6) 106·4 (98·1–114·7) 38·6 (34·1–43·1)
Ratio of infection-related severe maternal outcomes per 
1000 livebirths‡§
10·9 (9·8–12·0) 15·1 (12·0–18·2) 12·5 (10·8–14·3) 15·0 (11·8–18·3) 0·6 (0·0–1·1)
Ratio of infection-related maternal near-miss per 
1000 livebirths§
10·2 (9·1–11·2) 13·1 (10·3–16·0) 11·7 (10·0–13·4) 14·9 (11·7–18·0) 0·6 (0·0–1·1)
Data are n or ratio (95% CI). Country income level is based on the World Bank country income classification, 2018. *Suspected or confirmed infection. †Includes women who had an invasive procedure to treat the 
source of infection (vacuum aspiration, dilatation and curettage, wound debridement, drainage [incision, percutaneous, culdotomy], laparotomy and lavage, other surgery), admission to intensive care or high 
dependency unit, or transfer to another facility. Source of infection clinically, radiologically or microbiologically confirmed. ‡Maternal death or near-miss. §At least one WHO near-miss criteria. Geographical areas 
in six western European countries (Belgium, Denmark, Italy, Spain, the Netherlands, the UK) did not collect data on WHO near-miss criteria. 
Table 1: Study participants and ratios of maternal infection by country income level*
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post-partum or post-abortion and were identified at 
admission to the facility from home. Around a third were 
identified during pregnancy, not in labour, or were 
already hospitalised. Sociodemographic characteristics 
did not vary across the infection severity groups. Number 
of previous births, identification at post-partum or post-
abortion, and anaemia during pregnancy increased with 
severity of the infection.
At least one source of infection was identified for 
79·7% of women (table 3). The most common sources of 
maternal infections were of the genital (endometritis and 
chorioamnionitis) or urinary tract, skin or soft tissues, 
respiratory tract, and abortion-related. The most common 
source of infection leading to complications or severe 
maternal outcomes were endometritis, skin or soft 
tissue, and abortion-related.
Regarding the use of core practices for early identification 
and management of maternal infections, close to two-
thirds of women had a complete set of vital signs recorded, 
and 70·2% received antibiotics or other antimicrobials the 
day of suspicion or diagnosis of the infection (table 3). 
Less than half of the women had samples drawn for 
All women (n=2850) Less severe infections 
(n=1835)
Infections with 
complications* 
(n=634)
Infection-related 
severe maternal 
outcome† (n=381)
p value‡
Age, years ·· ·· ·· ·· <0·0009
<20 365 (12·9%) 245 (13·4%) 75 (11·9%) 45 (11·9%) ··
20–35 2104 (74·2%) 1357 (74·4%) 474 (75·0%) 273 (72·2%) ··
>35 365 (12·9%) 222 (12·2%) 83 (13·1%) 60 (15·9%) ··
Living with partner or spouse 2332 (88·1%) 1507 (88·1%) 511 (87·8%) 314 (88·7%) 0·78
Schooling, years ·· ·· ·· ·· 0·055
<5 174 (13·2%) 102 (12·4%) 40 (13·2%) 32 (16·6%) ··
5–8 327 (24·7%) 202 (24·5%) 79 (26·0%) 46 (23·8%) ··
9–11 450 (34·0%) 275 (33·3%) 110 (36·2%) 65 (33·7%) ··
>11 371 (28·1%) 246 (29·8%) 75 (24·7%) 50 (25·9%) ··
Number of previous births ·· ·· ·· ·· <0·0001
0 1250 (44·5%) 867 (47·9%) 264 (42·4%) 119 (31·6%) ··
1–2 1096 (39·0%) 689 (38·1%) 241 (38·7%) 166 (44·1%) ··
>2 463 (16·5%) 254 (14·0%) 118 (18·9%) 91 (24·2%) ··
Pregnancy status at the time of infection 
suspected or confirmed§
·· ·· ·· ·· <0·0001
Pregnant, not in labour 964 (33·9%) 749 (40·8%) 109 (17·2%) 106 (27·9%) ··
Pregnant, in labour 369 (13·0%) 303 (16·5%) 38 (6·0%) 28 (7·4%) ··
Post-partum 1246 (43·8%) 711 (39·1%) 347 (52·8%) 188 (49·5%) ··
Post-abortion¶ 269 (9·5%) 71 (3·9%) 140 (22·1%) 58 (15·3%) ··
Location at the time of infection suspected 
or confirmed§
·· ·· ·· ·· <0·0001
Arriving from home 1464 (51·5%) 985 (53·9%) 339 (53·6%) 140 (36·8%) ··
Transferred from another facility 382 (13·4%) 194 (10·6%) 86 (13·6%) 102 (26·8%) ··
Already hospitalised, non-intensive care 
unit
926 (32·6%) 650 (35·5%) 169 (26·7%) 107 (28·2%) ··
Already hospitalised in intensive care 
unit or high-dependency unit
70 (2·5%) 0 (0·0%) 39 (6·2%) 31 (8·2%) ··
Other complications
Anaemia during pregnancy, Hb <11 g/dL 799 (36·3%) 451 (32·6%) 190 (37·4%) 158 (51·1%) <0·0001
Pregnancy-related hypertension 296 (11·6%) 134 (8·5%) 77 (12·9%) 85 (22·3%) <0·0001
Pre-existing medical condition 169 (6·6%) 69 (4·4%) 38 (6·3%) 62 (16·3%) <0·0001
Post-partum haemorrhage|| 229/1861 (12·3%) 106/1184 (9·0%) 49/417 (11·8%) 74/260 (28·5%) <0·0001
Obstructed labour or dystocia|| 117/1633 (7·2%) 62/986 (6·3%) 33/387 (8·5%) 22/260 (8·5%) 0·12
Abortion-related haemorrhage¶ 127/322 (39·4%) 23/97 (23·7%) 65/158 (41·1%) 39/67 (58·2%) <0·0001
Data are n/N (%). *Includes women who had an invasive procedure to treat the source of infection (vacuum aspiration, dilatation and curettage, wound debridement, 
drainage [incision, percutaneous, culdotomy], laparotomy and lavage, other surgery), admission to intensive care or high dependency unit, or transfer to another facility. 
†Maternal death or near-miss. Geographical areas in six western European countries (Belgium, Denmark, Italy, Spain, the Netherlands, the UK) did not collect data for WHO 
near-miss criteria. ‡Multinomial mixed models adjusting for clustering at the country level. §Source of infection clinically, radiologically, or microbiologically confirmed. 
¶Women who had an abortion, ectopic, or molar pregnancy. ||Women who underwent childbirth (stillbirth or live birth).
Table 2: Demographic, obstetric, and clinical characteristics of women who had maternal infections by severity group
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culture at suspicion or confirmation of infection, and two-
thirds of the samples were taken before the administration 
of antibiotics. Microorganisms were reported in 21·2% of 
the samples, bacteria being the most frequent (77·1%); 
they are reported here without inferring direct causality. 
There were no marked differences in use of this core set 
All women (n=2850) Less severe infections 
(n=1835)
Infections with 
complications* 
(n=634)
Infection-related 
severe maternal 
outcome† (n=381)
p value‡
Primary source of infection identified§ 2271 (79·7%) 1368 (74·6%) 579 (91·3%) 324 (85·0%) <0·0001
Source of infection§
Urinary tract 632 (27·9%) 504 (36·8%) 69 (12·0%) 59 (18·2%) ··
Endometritis 343 (15·1%) 178 (13·0%) 88 (15·3%) 77 (23·8%) ··
Chorioamnionitis 338 (14·9%) 238 (17·4%) 66 (11·5%) 34 (10·5%) ··
Skin or soft tissue 336 (14·8%) 105 (7·7%) 185 (32·2%) 46 (14·2%) ··
Respiratory 204 (9·0%) 116 (8·5%) 21 (3·7%) 67 (20·7%) ··
Abortion-related¶ 193 (8·5%) 33 (2·4%) 115 (19·9%) 45 (13·9%) ··
Bloodstream 115 (5·1%) 97 (7·1%) 7 (1·2%) 11 (3·4%) ··
Peritonitis or abdominal cavity 69 (3·0%) 4 (0·3%) 27 (4·7%) 38 (11·7%) ··
Gastrointestinal 63 (2·8%) 39 (2·9%) 11 (1·9%) 13 (4·0%) ··
Breast 30 (1·3%) 22 (1·6%) 5 (0·9%) 3 (0·9%) ··
CNS 10 (0·4%) 3 (0·2%) 1 (0·2%) 6 (1·9%) ··
Other 197 (9·2%) 132 (10·6%) 42 (8·0%) 23 (7·1%) ··
Method of identification of the infection if source identified
Clinical examination alone 910 (40·1%) 526 (38·5%) 282 (48·7%) 102 (31·5%) ··
Clinical examination and laboratory test 890 (39·2%) 648 (47·4%) 159 (27·5%) 83 (25·6%) ··
Clinical examination and imaging 201 (8·8%) 85 (6·3%) 49 (8·5%) 67 (20·6%) ··
Clinical examination, laboratory, test, and imaging 267 (11·7%) 107 (7·8%) 88 (15·2%) 72 (22·2%) ··
Complete set of vital signs recorded on day infection was suspected 
or confirmed
1821 (63·9%) 1100 (59·9%) 435 (68·6%) 286 (75·1%) 0·0093
Antimicrobials started the day of suspicion or diagnosis of infection|| 1875 (70·2%) 1198 (70·6%) 435 (71·6%) 243 (66·4%) 0·37
Antibiotics started the day of suspicion or diagnosis of infection|| 1843 (70·2%) 1165 (70·5%) 435 (71·7%) 243 (66·4%) 0·58
Sample for culture drawn at any time** 1269 (46·6%) 788 (46·0%) 280 (44·7%) 201 (52·8%) 0·19
Sample for culture drawn before administration of antibiotics 760/1177 (64·6%) 496/745 (66·6%) 165/254 (65·0%) 99/178 (55·6%) 0·044
Any microorganism identified by any method†† 590 (21·2%) 360 (20·0%) 147 (25·6%) 101 (31·2%) 0·0017
Any positive culture of any body fluid** 579 (25·6%) 331 (24·2%) 133 (21·6%) 97 (26·1%) 0·011
All microorganisms identified by any methods‡‡
Bacteria 455 (77·1%) 257 (71·4%) 116 (87·2%) 82 (84·5%) ··
Fungi 47 (8·0 %) 30 (8·3%) 6 (4·5%) 11 (11·3%) ··
Parasite 94 (15·9%) 79 (21·9%) 7 (5·3%) 8 (8·2%) ··
Virus 21 (3·6%) 13 (3·6%) 3 (2·3%) 5 (5·1%) ··
Additional management to control the source of infection§§
Vacuum aspiration 108 (4·0 %) ·· 83 (13·0 %) 25 (7·0 %) ··
Dilatation and curettage 160 (5·6%) ·· 131 (20·7%) 29 (7·6%) ··
Wound debridement 162 (5·7%) ·· 136 (21·5%) 26 (6·8%) ··
Drainage (incision, percutaneous, culdotomy) 153 (5·4%) ·· 102 (16·0%) 51 (13·4%) ··
Hysterectomy 55 (1·9%) ·· 0 55 (14·4%) ··
Laparotomy and lavage 201 (8·0%) ·· 111 (17·5%) 90 (23·6 %) ··
Other surgery 86 (3·2%) ·· 64 (10·1%) 22 (5·8%) ··
Median length of stay in health facility, days (IQR) 5 (3–9) 5 (3–7) 7 (4–11) 9 (5–17) <0·0001
Admission to intensive or high dependency care 355 (13·8%) ·· 167 (27·7%) 188 (49·3%) <0·0001
Data are n (%), n/N (%), or median (IQR) unless specified. *Includes women who had an invasive procedure to treat the source of infection (vacuum aspiration, dilatation and curettage, wound debridement, 
drainage [incision, percutaneous, culdotomy] laparotomy and lavage, other surgery), admission to intensive care or high dependency unit, or transfer to another facility. †Maternal death or near-miss. 
Geographical areas in six western European countries (Belgium, Denmark, Italy, Spain, the Netherlands, the UK) did not collect data on WHO near-miss criteria. ‡Multinomial mixed models for percentages 
and linear model for logarithm (length of stay) adjusting for clustering at country level. §More than one source possible. ¶Women who had an abortion, ectopic, or molar pregnancy. ||Same day or previous 
day after 1800 h. **Includes culture drawn at entry in study or any time during stay in the facility. ††Includes culture of any body fluid, microscopy, or specific test (eg, malaria, tuberculosis, HIV). ‡‡Includes 
all organisms identified in women without inferring causation (when organism identified). Each woman could have more than one type of microorganism identified. §§More than one intervention possible. 
Table 3: Characteristics of maternal infections and management by severity group
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of practices for early identification and management of 
maternal infections across severity groups.
Table 4 shows pregnancy, maternal, and neonatal 
outcomes by pregnancy status at enrolment by infection 
severity group. Most women were discharged alive and 
had a live neonate who was discharged alive. Adverse 
pregnancy and neonatal outcomes increased with 
infection severity.
Discussion
This is the first study, to our knowledge, to provide data 
for frequency and management of maternal infections 
requiring hospital management in a large number of 
LMICs and HICs, and across the continuum of 
pregnancy and post-pregnancy periods up to 42 days. The 
observed frequency of suspected or confirmed maternal 
infections was of 70·4 pregnant or recently pregnant 
women per 1000 live births. The burden of intrahospital 
severe outcomes related to maternal infections is high, 
with more than a third of women who had an infection 
developing severe maternal outcomes or requiring 
invasive procedures to treat the source of infection, 
admission to an intensive care unit or high dependency 
care, or transfer to another facility. Lack of adequate 
assessment of vital signs and delays in antimicrobial 
therapy were frequent.
Our results suggest that there are marked differences 
in frequency of infections and outcomes of maternal 
infections between LMICs and HICs. The burden of 
infection-related severe maternal outcomes is lower in 
HICs compared with LMICs, as previously described.7,8,11,12 
Although we found rates of infection-related severe 
maternal outcomes in HICs similar to those previously 
reported,7,8,12 rates in LMICs are much higher in our 
All women 
(n=2850)
Maternal infection first suspected or diagnosed during pregnancy or 
labour
Maternal infection first suspected or diagnosed during post-partum or 
post-abortion
All women 
who were 
pregnant or in 
labour 
(n=1335)
Less severe 
infections 
(n=1053)
Infections with 
complications* 
(n=147)
Infection-
related severe 
maternal 
outcome† 
(n=135)
p value‡ All women
puerperium 
(n=1515)
Less severe 
infections 
(n=782)
Infections with 
complications* 
(n=487)
Infection-
related severe 
maternal 
outcome† 
(n=246)
p value‡
Pregnancy 
outcome§
·· ·· ·· ·· ·· <0·0001 ·· ·· ·· ·· <0·0001
Still pregnant 662 (23·3%) 662 (49·7%) 549 (52·2%) 59 (40·1%) 54 (40·0%) ·· ·· ·· ·· ··
Abortion¶ 322 (11·3%) 53 (4·0%) 26 (2·5%) 18 (12·3%) 9 (6·6%) ·· 269 (17·9%) 71 (9·2%) 140 (28·7%) 58 (23·5%) ··
Stillbirth 131 (4·6%) 51 (3·9%) 21 (2·0%) 11 (7·5%) 19 (14·1%) ·· 80 (5·3%) 29 (3·7%) 21 (4·4%) 30 (12·2%) ··
Livebirth 1730 (60·8%) 567 (42·5%) 455 (43·3%) 59 (40·1%) 53 (39·2%) ·· 1163 (77·0%) 679 (87·1%) 326 (66·9%) 158 (64·2%) ··
Final mode of 
birth§||
·· ·· ·· ·· ·· 0·0007 <0·0002
Vaginal birth 793 (44·3%) 301 (50·3%) 248 (53·9%) 25 (36·8%) 28 (39·4%) ·· 492 (41·3%) 321 (46·6%) 106 (32·5%) 65 (36·7%) ··
Caesarean 
section
998 (55·7%) 298 (49·7%) 212 (46·1%) 43 (63·2%) 43 (60·6%) ·· 700 (58·7%) 368 (53·4%) 220 (67·5%) 112 (63·3%) ··
Maternal status 
at end of 
follow-up**
·· ·· ·· ·· ·· <0·0001 ·· ·· ·· ·· <0·0001
Discharged 
alive
2775 (97·5%) 1302 (97·8%) 1050 (100%) 134 (91·8%) 118 (87·4%) ·· 1473 (97·2%) 782 (100%) 477 (98·0%) 214 (87·0%) ··
Transferred 45 (1·6%) 19 (1·4%) ·· 12 (8·2%) 7 (5·2%) ·· 26 (1·7%) ·· 10 (2·0%) 16 (6·5%) ··
Passed away 26 (0·9%) 10 (0·8%) ·· 0 10 (7·4%) ·· 16 (1·1%) ·· 0 16 (6·5%) ··
Neonatal status 
at end of 
follow-up§††
·· ·· ·· ·· ·· <0·0001 ·· ·· ·· ·· 0·095
Discharged 
alive
1551/1834 
(84·5%)
544/643 
(84·6%)
436/517 
(84·4%)
59/68  
(86·8%)
449/58 
(84·5%)
·· 1007/1191 
(84·5%)
623/699 
(89·1%)
265/331 
(80·0%)
119/161 
(73·9%)
··
Early 
neonatal 
death
67/1834 
(3·7%)
23/643  
(3·6%)
12/517  
(2·3%)
5/68  
(7·4%)
6/58  
(10·3%)
·· 44/1191 
(3·7%)
19/699 
(2·7%)
17/331  
(5·1%)
8/161  
(5·0%)
··
Unknown 216/1834 
(11·8%)
76/643 
(11·8%)
69/517  
(13·3%)
4/68  
(5·9%)
3/58  
(5·2%)
·· 140/1191 
(11·8%)
57/699 
(18·2%)
49/331 
(14·8%)
34/161 
(21·1%)
··
Data are n (%) or n/N (%), unless specified. Percentages were calculated using available data. *Includes women who had an invasive procedure to treat the source of infection (vacuum aspiration, dilatation and 
curettage, wound debridement, drainage [incision, percutaneous, culdotomy], laparotomy and lavage, other surgery), admission to intensive care or high dependency unit, or transfer to another facility. †Maternal 
death or near-miss. Six western European countries (Belgium, Denmark, Italy, Spain, the Netherlands, the UK) did not collect data for WHO near-miss criteria. ‡Multinomial mixed models adjusting for clustering at 
country level. §Includes data for multiple pregnancies. ¶Women who had an abortion, ectopic, or molar pregnancy. ||Women who underwent childbirth (stillbirth or livebirth). **Discharge from health facility, 
transfer outside the geographical area or death. ††Newborns born alive, end of follow-up was at discharge from facility after birth, transfer outside the geographical area, death, or day 7 after birth if still hospitalised.  
Table 4: Pregnancy, maternal, and neonatal outcomes by pregnancy status at entry in the study and severity group
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sample, particularly in upper-middle-income countries.11 
The observed variation across countries could be related 
to use of different admission criteria or resources 
available to identify severe conditions or to manage in-
patient women with infections across facilities, 
geographical areas, and countries. This difference in 
identification and management of women with infection 
could partly explain the higher burden of infectious 
morbidities in upper-middle-income countries than 
lower-middle-income countries, where facilities might 
have lower thresholds for admission of women with 
maternal infection or more resources to identify or treat 
compli cations compared with facilities in low-income 
countries.
Infections were the underlying cause of most 
intrahospital deaths attributed to other direct (eg, abortion-
related) and indirect (eg, respiratory infection, menin-
gitis) causes. Infections were also present in about a third 
of deaths attributed to other causes, in concurrence 
with previous findings in obstetric,20–23 and general 
populations.10 These results suggest that the role of 
infections as an underlying or contributing cause of 
maternal deaths, across the continuum from pregnancy 
to post-partum or post-abortion, is higher than previously 
thought. As previously suggested, the inclusion of non-
obstetric wards in our study might have led to an increase 
in identification of maternal deaths and near-miss 
cases related to indirect infections.20 This finding 
could also reflect a trend towards an increasing proportion 
of indirect causes of maternal deaths, although the 
contribution of infections as a direct cause of severe 
maternal outcomes remains high.20,24 It is worth noting 
that the distribution of causes of intrahospital maternal 
deaths is close to the most recent estimates of causes of 
maternal mortality.1
The most common infections identified in this study 
were urinary tract infections, endometritis, chorio-
amnionitis, abortion-related infections, and skin and soft 
tissue, in line with previous studies.2,8,25 Several of the 
obstetric infections identified in our sample and asso-
ciated with severe maternal outcomes, namely skin and 
soft tissue and abortion-related infections, are highly 
preventable. Good infection control measures are key for 
the prevention of infections after caesarean section, 
episiotomy, or other invasive procedures.15,16,26 In addition, 
prophylactic antibiotics are recommended to reduce 
infections due to caesarean section. However, data for 
coverage of prophylactic antibiotics for caesarean section 
suggest that its use is suboptimal across the world,2,27 
with wide variations across health facilities.28 Post-
abortion infections are preventable through access to 
safe abortion, and prompt appropriate management of 
abortion-related complications.16
This study highlights important gaps regarding early 
identification and management of maternal infections in 
health facilities. A complete set of vital signs on the day 
of suspicion or diagnosis of infection was not reported 
for a third of women. Although most women received 
antimicrobials around the time of suspicion or diagnosis 
of the infection, about a third did not, and fewer than half 
had samples drawn for cultures before administration of 
antibiotics. In general, women with severe maternal 
outcomes had fewer invasive procedures to control the 
source of infection. Previous studies have also reported 
inadequate recognition and management of women with 
infection and sepsis in LMICs20,29 and HICs,8,28 including 
incomplete monitoring and delayed initiation of anti-
biotics. A substantial opportunity exists for improve ment 
in early identification and prompt management of 
women with infections in health facilities, requiring 
more than just raising awareness.19 The use of quality 
improvement initiatives, including bundles, protocols, 
and checklists contribute to improving practices and 
outcomes. The use of trigger tools has shown an increase 
in the recording of vital signs and improved manage-
ment.17 Timely completion of bundles of care (1 h and 3 h 
bundles) has also been associated with a reduction in 
adult mortality.14 These strategies should also contribute 
to better antimicrobial stewardship and strengthen 
efforts to minimise antimicrobial resistance.13,15,30
Our study is one of the few to report data for maternal 
infections in the continuum of pregnancy, childbirth, 
and the post-partum or post-abortion period, and across 
different severity groups. We sought to identify women 
with maternal infections by ensuring a good coverage of 
facilities within geographical areas, including partici-
pation of non-obstetric wards. The awareness campaign 
might have contributed to better identification of eligible 
cases. However, generalisability of results is limited to 
intrahospital outcomes and geographical areas similar to 
those included in the study. Comparisons with other 
studies reporting on the burden of infections and sepsis 
are limited by differences in case definitions, sources of 
infections considered, or stage of pregnancy included.8,25 
Temporality of organ dysfunction and infection was 
difficult to assess in our study, which might result in 
overestimating sepsis cases. However, as discussed in 
previous studies, diagnosing infection and attributing 
organ dysfunction to infection are often subjective.30 
Reverse causality might also complicate this association 
in cases of multiple maternal complications—eg, 
infection and post-partum haemorrhage.21 A detailed 
description of strategies put in place to address potential 
sources of selection and measurement bias in our study 
is presented in the published protocol.18 We expected a 
minimal effect of geographical or seasonal clusters of 
infectious morbidities given the large number of 
countries distributed between the northern and southern 
hemispheres and that most of the cases would be 
genitourinary tract infections not subjected to seasonality. 
Our study did not evaluate infections not requiring 
hospital management and was not designed to cover 
maternal infection-related deaths in the community. 
Inclusion in the study was based on standard routine 
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care in participating health facilities, including admission 
and diagnosis criteria, as well as collection of any 
laboratory, diagnostic, or other investigations. However, 
in women with complications or severe maternal outc-
omes, we would not have expected differing admission 
thresholds. This group is likely to have needed in-hospital 
management regardless of the admission criteria or 
resources available, in particular for women with 
infection-related near-miss who otherwise would have 
died if not treated in the facility. We did not collect the 
time of initiation of antimicrobials and therefore were 
not able to evaluate compliance with 3 h and 6 h sepsis 
bundles. The study design did not enable us to evaluate 
the long-term effects of maternal infections, including 
for example readmission or death after discharge, or 
infertility.7,8
The frequency of infections among pregnant or recently 
pregnant women requiring management in health 
facilities is high. Our results suggest that contribution of 
direct and indirect infections to overall maternal deaths is 
greater than previously thought. There is a substantial 
opportunity to improve the prevention, early identifi cation, 
and prompt management of women with infections in 
health facilities by implementing effective evidence-based 
practices.
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